Obesity in women decreases risk of glaucoma

Article

Females with a higher body mass index (BMI) are less likely to develop open-angle glaucoma (OAG).

Females with a higher body mass index (BMI) are less likely to develop open-angle glaucoma (OAG), according to a recent study published in the Archives of Ophthalmology.

Dr Wishal D. Ramdas et al., Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands, conducted the prospective population-based cohort Rotterdam Study on 3939 participants without OAG. The initial purpose of the investigation was to determine whether factors such as socioeconomic status, smoking, alcohol consumption and obesity influence the development of OAG.

The same ophthalmologic examinations were performed on all participants, including intraocular pressure measurements, optic nerve head assessment and perimetry.

Of 3939 participants, 108 contracted OAG during 9.7 years' mean follow-up. The findings show that for every unit increase in BMI in women, the risk of developing OAG increases by 7%. No significant results were found for socioeconomic status, smoking and alcohol consumption. There were no associations between obese males and glaucoma.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.